May 5, 2015
Research Triangle Park, NC
The standards applied to the patentability of inventions in oncology and biotechnology have been dramatically altered in the last few years. Among the significant changes is the U.S. Supreme Court's 2013 ruling that the isolated human BRCA1 and BRCA2 genes used by Myriad Genetics to test for breast cancer were "unpatentable subject matter."
Oncology and biotech companies will need to make major changes to their business, research, and patent strategies to account for these developments.
During this seminar, held in conjunction with the Southeast Investor & Venture Philanthropy Oncology Summit 2015, attendees will learn about recent changes in patent law relating to patent-eligible subject matter—as well as the strength of disclosure required—and learn how to use these changes as tools rather than hurdles. Topics include:
Who Should Attend:
Business executives, in-house IP counsel, R&D partners, venture philanthropy and VC analysts, university researchers, and technology transfer officers.
Registration:
There is no charge to attend the program. Register by Friday, May 1, 2015. Space is limited, so please register early.
Time:
4:30 – 6:00 p.m. Reception (with Oncology Summit attendees)
6:00 – 7:30 p.m. Program
7:30 – 8:00 p.m. Dessert and Networking Reception
Location:
North Carolina Biotechnology Center
15 T.W. Alexander Drive
Research Triangle Park, NC 27709
Speakers:
Mark J. Feldstein, Ph.D.
Ryan P. O'Quinn, Ph.D.
Anil K. Goyal, Ph.D., Heat Biologics, Inc.
William T. Lee, Ph.D., RAC, Cato Research, Ltd.
In Partnership with the North Carolina Biotechnology Center
Hybrid Conference
2024 California Intellectual Property Law Institute
October 21-22,2024
San Francisco
Conference
2024 Licensing Executives Society USA – Canada Annual Meeting
October 20-23, 2024
New Orleans
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.